Andrea Iannone suspended from all competition after failed drug test

Aprilia MotoGP star tested positive for performance-enhancing steroids at Malaysia round.


Italian racer Andrea Iannone has been suspended from all competitions by the FIM after failing a drug test at the Malaysia round of MotoGP on November 3 2019. According to a release from GP bosses, a WADA (World Anti-Doping Agency) approved laboratory found an Adverse Analytical Finding of a banned substance, reported as nandrolone by several media outlets.

Here’s the full text of the release:

Article continues below...
Advert

Enjoy more Fast Bikes reading in the monthly magazine.
Click here to subscribe & save.

The Fédération Internationale de Motocyclisme (FIM) has advised Italian Grand Prix rider Andrea Iannone that he is provisionally suspended pursuant to Article 7.9.1 of the 2019 FIM Anti-doping Code (CAD). The decision to provisionally suspend Mr Andrea Iannone was mandatory following the receipt of a report from the WADA accredited laboratory in Kreischa b. Dresden (Germany) indicating an Adverse Analytical Finding of a non-specified substance under Section 1.1.a) Exogenous Anabolic Androgenic Steroids (AAS) of the 2019 Prohibited List, in a urine sample collected from him at an in-competition test carried out by the FIM at the round of the FIM Grand Prix World Championship held in Sepang, Malaysia on 3 November 2019.

Mr Andrea Iannone has the right to request and attend the analysis of his B sample.

Mr Andrea Iannone is provisionally suspended with effect from 17 December 2019. He is therefore barred from participating in any motorcycling competition or activity until further notice. Under Article 7.9.3.2 CAD, Mr Iannone may request lifting of his provisional suspension.

Article continues below...
Advert

Under the World Anti-Doping Code and the FIM Anti-Doping Code, the FIM is unable to provide any additional information at this time.

Subscribe to Fast Bikes Magazine Enjoy more Fast Bikes reading in the monthly magazine. Click here to subscribe.